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1. Introduction 
Androgens and the androgen receptor have been implicated in a number of human diseases 
and conditions, most notably prostate cancer. [1] Huggins and Hodges in 1941 
demonstrated that bilateral orchiectomy or estrogen treatment is an effective treatment for 
prostate cancer.[2] Based upon their findings, androgen deprivation therapy (ADT) has 
remained the main therapeutic option for patients with advanced prostate cancer for about 
70 years. Different therapeutic approaches, including surgical or medical castration with 
gonadotropin-releasing hormone (GnRH) agonists, and an antiandrogen therapy, have 
become the gold standard for prostate cancer treatment with metastases. ADTs are quite 
successful, leading to regression of tumors in a majority of cases; however, 12-18 months 
later, most prostate cancers recur in a more aggressive, castration-resistant form (castration-
resistant prostate cancer (CRPC)) that is incurable. Median survival for these patients after 
recurrence is 24-36 months.[3, 4] New ADTs and other promising therapies for CRPC have 
been actively developed.[5] This review will provide an overview of prostate cancer 
aggressiveness and the androgen levels in blood and prostatic tissues, androgen milieu 
during ADT, androgen milieu during CRPC, and the prospects of ADT on the ground of the 
androgen milieu in the prostate. 
2. Androgen milieu in blood 
Biosynthetic pathway for androgen synthesis is the -5 pathway in primates like humans. 
[6] (Fig. 1) As a result, a large amount of dehydroepiandrosterone (DHEA) and DHEA 
sulfate (DHEA-S) are in the blood in humans. In rodents, biosynthetic pathway for 
androgen synthesis is the -4 pathway. In human males, testosterone is the major 
circulating androgen. More than 95% of testosterone is secreted by the Leydig cells, 
situated in the testicular interstitium, while the adrenal cortex also contributes to this 
production. [7, 8] The Leydig cells produce testosterone in response to hormonal 
stimulation by the pituitary gonadotropin luteinizing hormone (LH). Testosterone plays a 
key role in health and well-being as well as in sexual functioning. Testosterone effects can 
be classified as virilizing and anabolic effects including growth of muscle mass and 
strength, increased bone density and strength. Serum testosterone levels decline with 
advancing age. [9] Recently, a pooled analysis of moderately sized prospective studies 
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including 3886 cases of prostate cancer and 6438 matched controls reported no association 
of circulating androgens and risk of prostate cancer, either overall or for subgroups 
according to tumor stage or grade. [10] Prostate cancer risk and tumour aggressiveness 
are not related to serum levels of total and free testosterone. [11] However, this negative 
result does not deny the role of androgens for the prostate cancer, rather emphasizes the 
importance of the androgen metabolism in the prostate. It is not clear to what extent the 
testosterone and dihydrotestosterone (DHT) in the prostate derive from adrenal 
androgens or other steroid precursors. 
 
 
 
 
 
*b5: cytochrome-b5 reductase 
CYP17A1: Cytochrome P450, family 17, subfamily A, polypeptide 1 
DHEA: dehydroepiandrosterone 
DHT: dihydrotestosterone 
HSD: hydroxysteroid dehydrogenase 
5┙-Rs: 5--reductases 
Fig. 1. The androgen metabolic pathway and enzyme related products of human being. 
Biosynthetic pathway for androgen synthesis is the -5 pathway in primates like humans. 
As a result, a large amount of DHEA and DHEA-S is in the serum in humans. 
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3. Androgen milieu in the prostate 
Testosterone and DHT can be synthesized from DHEA with various androgen synthetic 
enzymes in the human prostate. The conversion of testosterone from 17-ketosteroid, 
androstenedione, is said to be catalyzed by the 17-hydroxysteroid dehydrogenase (HSD) 
type 1, 3, 5, 12. [12] 17-HSD type3 is mainly expressed to convert into testosterone from 
androstenedione in the testis. Aldo-keto reductase family 1, member C3㸦AKR1C3㸧, 
known as 17-HSD type5, is mainly expressed to convert into testosterone from 
androstenedione in the prostate. [13] Humans have three isoenzymes of 5--reductase. Both 
type 1 and type 2 5--reductase catalyze the conversion of testosterone to DHT. [14, 15] 
Type 1 enzyme (encoded by SRD5A1) is expressed mostly in skin and hair, while type 2 
enzyme (encoded by SRD5A2) is located primarily in androgen target tissues, including 
genital skin and prostate. Recently, the existence of 5--reductase type 3 (encoded by 
SRD5A3) is identified. [16] Godoy et al. showed that expression of 5-reductase type 3 in 
''classical'' as well as ''non-classical'' androgen-regulated tissues is consistent with 5-reductase 
type 3 enzyme having functions other than converting testosterone to DHT in human tissues, 
such as participation in the N-glycosylation process. [17] They also showed that over-
expression of 5-reductase type 3 in breast, testis, lung, thyroid, and particularly prostate 
cancer, compared to their benign counterparts, suggests a potential role for 5-reductase type 
3 as a biomarker of malignancy, and over-expression of 5-reductase type 3 in androgen 
sensitive prostate cancer and CRPC suggests a potential role for this enzyme in synthesizing 
DHT in both an androgen-stimulated and an androgen-deprived human prostate 
microenvironment. Therefore, the prostate is not only the androgen dependent organ but also 
the androgen productive organ. Recently, DHT mainly synthesizes via testosterone as stated 
above, but also synthesizes without testosterone biosynthesis, 'backdoor' pathway. [14, 18, 19] 
An alternate 'backdoor' pathway to DHT was elucidated in the tammar wallaby pouch young, 
and studies in knockout mice showed that this pathway uses 5--reductase type 1 to convert 
17-hydroxyprogesterone to 5--reduced androgen precursors.[20] The role of 'backdoor' 
pathway to DHT in human androgen metabolism, however, is not clear yet. The traditional 
belief that prostate cancer growth is dependent on the serum testosterone level has been 
challenged by recent negative studies in non-castrated men.[21, 22] The evidence clearly 
indicates that there is a limit to the ability of androgens to stimulate prostate cancer growth. A 
Saturation Model based on androgen-AR binding provides a satisfactory conceptual 
framework to account for the dramatic effects seen with castration as well as the minor impact 
of testosterone administration in non-castrated men.[23] 
4. Prostate cancer aggressiveness and the androgen milieu in the prostate 
and in blood 
Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. 
Large prospective study and a pooled analysis of moderately sized prospective studies did 
not show convincing evidence of a relationship between serum sex hormones and prostate 
cancer. [10, 24] However, these negative results do not deny the role of androgens for the 
prostate cancer, rather emphasizes the importance of the androgen metabolism in the 
prostate. It is not clear to what extent the testosterone and DHT in the prostate derive from 
adrenal androgens or other steroid precursors. The 90-95% decrease in serum testosterone is 
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observed after castration; however, the prostate efficiently transforms the adrenal androgen 
precursors DHEA-S, DHEA, and androstenedione into the active androgens, testosterone 
and DHT. All the enzymes are reported to exist in the prostate metabolizing from androgen 
precursors to testosterone and DHT. [25] The plasma concentration of DHEA-S is 100-500 
times higher than that of testosterone. [26] High circulating levels of DHEA-S provide large 
amounts of the precursors required for conversion into active androgens in the prostate. The 
active androgens made locally in the prostate act in the prostate. In our data, the level of 
DHT in the prostate before ADT was not correlated with the serum level of testosterone, but 
was correlated with the serum level of DHEA and DHEA-S.[26] These results suggested that 
DHT in the prostate comes not only from testosterone produced in the testes, but also from 
adrenal androgens. There are still many questions about the androgen environment in the 
prostate in patients with prostate cancer. There have been few reports about the relations 
between histological aggressiveness and the DHT levels in the prostate in patients with 
prostate cancer. We revealed that the DHT levels in the prostate in patients with Gleason 
scores of 7 to 10 were significantly lower than those with Gleason scores of 6 and under, 
although there were no significant differences between the patients with Gleason scores of 7 
to 10 and the patients with Gleason scores of 6 and under prostate cancer with respect to 
serum levels of androgens. [27] The result of the association between the DHT level in the 
prostate and the Gleason score gives useful information to predict the biological 
aggressiveness of prostate cancer and consider the treatment of the patients with such 
cancers. One hypothesis as to the correlation between clinical aggressiveness and low 
androgen levels in the prostate is that the hormonal milieu with low androgen levels might 
be varied enough to disrupt the normal growth and maintenance of the prostate tissue, and 
may cause the resultant compensatory hyperplasia that increases the risk of a consequent 
selection of androgen independent, aggressive prostate cancer formation due to low 
androgen levels. [28] Several studies suggested that men with smaller prostates had more 
high-grade cancers and more advanced diseases. [29-31] Prostate size was inversely 
associated with the risk of high grade cancer. The Prostate Cancer Prevention Trial (PCPT), a 
Phase III, randomized, double-blind, placebo-controlled trial of finasteride, a 5--reductase 
inhibitor, for the prevention of carcinoma of the prostate was held. [32] A total of 18,882 
essentially healthy men, aged 55 and older, had been randomized to receive finasteride (5 
mg daily) or placebo for seven years. PCPT results suggested that finasteride could reduce 
the frequency of prostate cancer by 25% compared with placebo. However, the patients with 
Gleason scores of 7 to 10 were detected significantly more frequently in the finasteride 
group than in the placebo group. Several questions were raised by the results of the trial that 
finasteride could induce the development of high grade disease. They did not find evidence 
that the drug caused changes in tumor composition that might contribute to aggressive 
cancer, though they don't entirely rule out the possibility that finasteride may have led to 
high-grade prostate cancer in some men in the study. One possible explanation was the 
occurrence of over-grading due to histological alterations. Several reports, however, showed 
that although finasteride use might cause some alterations in the assignment of the Gleason 
grade, a consistent hormonal therapy effect with finasteride treatment has not been 
observed. [33] Lucia et al. revealed that finasteride may have contributed to the increased 
rate of high-grade cancers detected in the PCPT by making the prostate smaller, helping the 
biopsy find the cancer. [34] Moreover, the results of the Reduction by Dutasteride of 
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Prostate Cancer Events (REDUCE) trial using the dual 5--reductase isoenzyme inhibitor 
dutasteride, has recently been reported.[35] The REDUCE trial, contrary to the Prostate 
Cancer Prevention Trial (PCPT), is performed in 8,231 men ages 50-75, who would have 
been candidates for biopsy anyway because of PSA values of 2.5 - 10 ng/ml. Although 
over the course of 4 years, significantly fewer prostate cancers were detected in men 
taking dutasteride than in those taking placebo, representing a relative risk reduction of 
22.8% (P <0.001), there were 12 tumors with a Gleason score of 8 to 10 in the dutasteride 
group, as compared with only 1 in the placebo group (P=0.003). These findings and our 
results suggest that biologically aggressive prostate cancer can exist under a low DHT 
environment, and may proliferate under the low DHT environment with finasteride or 
dutasteride medication where the prostate cancer of a low malignancy with high DHT 
dependency cannot easily exist. High levels of androgen receptor (AR) are said to be 
associated with the increased proliferation, markers of aggressive disease, and to be 
predictive of decreased biochemical recurrence-free survival independently. [36] This 
confirms the role of AR in tumor growth and progression in hormonally naive prostate 
cancer. Several reports and our results revealed that 17-HSD5 (known as AKR1C3) 
positive cases were significantly associated with clinical stage. [37, 38] Fung et al. revealed 
that elevated expression of AKR1C3 is highly associated with prostate cancer. [37] We also 
revealed that both AR and androgen-converting enzymes were up-regulated in the high-
grade or advanced prostate cancer. [38] AKR1C3 (17-HSD5) may be involved in increasing 
the local concentration of testosterone in prostate cancer tissues, resulting in the progression, 
invasion and further development of prostate cancer following ADT. 
5. Intraprostatic androgen milieu during androgen deprivation therapy 
The castration level of serum testosterone is disputed; however, historically, circulating 
testosterone levels have been used to assess the efficacy of androgen depletion with a target 
total testosterone level below 50 ng/dl (<1.74 nmol/l). [39-42] In men with prostate cancer, 
orchiectomy reduces serum testosterone to anorchid levels within 12 hours. The clinical 
significance of different serum levels of testosterone yielded during ADT has not yet been 
well elucidated. The serum testosterone level in men being treated with ADT has never been 
categorically established. [43] The typical serum testosterone level in men after an 
orchiectomy is 14 ng/dl, which is equivalent to 0.5 nmol/l. Over the years, there have been 
many specialists who have argued that the appropriate serum testosterone level for a man 
who is being well-controlled on ADT should, in fact, be < 20 ng/dl (0.7 nmol/l). Morote et 
al. have shown that 25% of men receiving continuous ADT with a GnRH agonist have a 
serum testosterone level > 50 ng/dl. [44] Forty-four percent of the same group of men 
studied had a serum testosterone level that was consistently < 20 ng/dl. Also, in the same 
group of men, they demonstrated a direct correlation between serum testosterone levels and 
time to development of CRPC. Perachino et al. have also reported a significant association 
between serum testosterone levels 6 months after initiation of ADT and overall survival. [45] 
Several reports showed that DHT in the prostate after ADT is supplied by the precursors of 
androgens from the adrenal origin. We showed that after ADT with castration and 
flutamide, the DHT level in the prostatic tissue remained at approximately 25% of the 
amount measured before ADT in the same patients. [26] Previous reports revealed that the 
mean DHT levels in the prostate tissue treated with ADT were between 10% and 40% of 
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those of untreated. [26, 46-50] Testosterone is converted to DHT by 5- reductase in the 
prostate. Labrie et al. showed that even if testosterone levels in blood drop to low levels 
by castration, DHT levels in the prostate were maintained about 40% before the treatment. 
[47] These results showed that the considerable levels of DHT exist in the prostate after 
castration. We also revealed that the levels of DHT in the prostate before ADT were 
correlated with the serum levels of adrenal androgens. [26] We could not recognize the 
correlation between testosterone levels in blood and DHT levels in the prostate before the 
treatment; however, we recognized the correlation between DHT levels in the prostate 
and DHEA levels (or DHEA-S levels) in blood. The levels of DHT in the prostate after 
ADT using a GnRH agonist and flutamide were also correlated with the serum level of 
testosterone. The serum DHT levels after ADT were correlated with serum levels of 
adrenal androgen. The testosterone levels in blood after ADT are supplied from the 
adrenal androgen precursors converted in the prostate, and the adrenal androgen 
precursors are converted into DHT in the peripheral organs including the prostate. These 
results showed that DHT in the prostate can be made not only from testosterone derived 
from the testis but also from the adrenal precursors. These findings suggest that serum 
testosterone after ADT mostly comes from adrenal androgens converted in the prostatic 
cells. These results revealed that the prostate is the main DHT producing organ and DHT 
levels in the prostate are correlated with the adrenal androgen precursor levels and 
testosterone levels in the prostate. 
Substantial levels of DHT remain in the prostate after castration; however, the influence on 
the change in the DHT levels in the prostate before and after ADT in connection with 
prostate cancer aggressiveness has not yet been elucidated. We revealed that the change in 
the DHT levels before and after ADT in the prostate with the prostate cancer of Gleason 
scores of 7 to 10 was significantly smaller than that in the prostate with the prostate cancer 
of Gleason scores of 6 or less.[51] Recently, 5--reductase type 1(SRD5A1) is reported to 
express in aggressive and recurrent prostate cancer. [38,52, 53] Arai et al. showed that the 
levels of adrenal androgens in prostate cancer tissues after ADT were similar to those in 
untreated prostate cancer. [54] Especially, DHEA was the most existing androgen precursor 
in prostate cancer tissues after ADT. The levels of DHEA were high in prostate cancer 
tissues, irrespective of ADT. They assumed that DHEA played a significant role in the 
synthesis of testosterone and DHT in prostate cancer tissues after ADT. Several reports 
revealed that AR signaling pathway is an important mechanism in proliferation of 
aggressive prostate cancer during ADT.[55] Stanbrough et al. revealed that AR 
transcriptional activity is reactivated in androgen-independent prostate cancer and 
identifies the intracellular conversion of adrenal androgens to testosterone as a mechanism 
mediating this reactivation. [56] These findings and our results suggest that the low DHT 
levels in the prostate with aggressive prostate cancers are probably sufficient to propagate 
the growth of the tumor, and the prostate with aggressive prostate cancer can produce 
androgens from the adrenal precursors more autonomously than that with non-aggressive 
prostate cancer does under the low testosterone environment with testicular suppression. 
Mostaghel et al. showed that the reduction of circulating androgens to castrate levels and 
interruption of AR signaling by androgen deprivation are neither reliably effective nor 
uniform in suppressing prostatic androgen-regulated gene and protein expression.[57] Their 
findings suggest that medical castration based on serum testosterone levels cannot be 
equated with ablation of androgen levels or androgen-mediated activity in the prostate 
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tissue microenvironment. These findings underscore the need for demonstrating 
suppression at the target tissue and molecular level before drawing conclusions regarding 
the clinical efficacy of hormonal treatment strategies. We showed that the serum PSA levels 
well reflect the androgen milieu in localized prostate cancer patients receiving ADT, which 
can be explained by the Saturation Model and disease control. [58] The androgen milieu in 
men with high Gleason score prostate cancer is probably less affected by conventional ADT 
than that in men with low score cancer, which was suggested to be associated with adrenal 
androgen levels. We also showed that in patients treated with ADT the pituitary-adrenal axis 
mediated by adrenocorticotropic hormone has a central role in the regulation of androgen 
synthesis. [59] Serum adrenocorticotropic hormone and adrenal androgen concentrations were 
correlated with the post-treatment PSA. Adrenocorticotropic hormone mediated androgen 
synthesis is a potential target for advanced androgen deprivation therapy. 
6. Androgen milieu in the castration-resistant prostate cancer 
The pathogenesis of CRPC involves a mixture of multiple pathways that increase and 
broaden the function of the AR, and others that bypass the AR.[60] Analysis of tumor 
samples from patients with CRPC has revealed several mechanisms utilized by tumor cells 
to reactivate the AR signaling at sub-physiological serum concentration of androgens or 
even in the presence of AR antagonists.[61] CRPC has been used synonymously with 
androgen-independent prostate cancer and hormone-refractory prostate cancer but is the 
preferred term, as we now know that many men with CRPC respond to additional 
manipulations that ablate or block prostate cancer growth stimulation by androgens. CRPC 
is clinically detected by a rise in PSA, typically defined as three consecutive rises over nadir 
in the context of castrate levels of serum testosterone and after anti-androgen withdrawal 
for at least 4 weeks and despite secondary hormonal manipulations and/or radiologic 
progression. In the face of testicular androgen suppression the adrenal androgens DHEA, 
DHEA-S and androstenedione retain the potential to stimulate prostate cancer growth since 
these steroids are converted to testosterone and DHT in the prostate, which are active 
androgens even after prostate cancer acquires the ability to activate during ADT. Chen et al. 
showed that a modest increase in AR mRNA was the only change consistently associated 
with the development of resistance to anti-androgen therapy.[62] This increase in AR 
mRNA and protein was both necessary and sufficient to convert prostate cancer growth 
from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional 
ligand-binding domain. Conventional AR antagonists showed agonistic activity in cells with 
increased AR levels; this antagonist-agonist conversion was associated with alterations in 
the recruitment of coactivators and corepressors to the promoters of AR target genes. 
Increased levels of AR confer resistance to anti-androgens by amplifying signal output from 
low levels of residual ligands, and by altering the normal response to antagonists. Mohler et 
al. revealed that recurrent prostate cancer may develop the capacity to biosynthesize 
testicular androgens from adrenal androgens or cholesterol. [63, 64] They showed that tissue 
levels of testosterone were similar in recurrent prostate cancer and benign prostate. They 
also showed that the DHT level in recurrent prostate cancer tissue was decreased to 18% of 
the level in benign prostate tissue. Testosterone and dihydrotestosterone occur in recurrent 
prostate cancer tissue at levels sufficient to activate AR. Montgomery et al. showed that soft 
tissue metastases in patients with anorchid serum testosterone contain levels of testosterone 
that are up to three times higher than those in prostate tumors in eugonadal men.[65] 
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Transcript levels of enzymes involved in androgen synthesis were up-regulated in the same 
tumors, suggesting that tumoral synthesis of androgens from cholesterol might occur.[66] 
Androgen-independent prostate cancer cell lines synthesize testosterone from radio-labeled 
cholesterol in vitro, and human prostate cancer xenografts are capable of synthesizing DHT 
from acetate and cholesterol, confirming that tumoral androgen synthesis is possible.[67] 
Thus, experimental and clinical evidence suggests that the enzymes of steroid metabolism 
are activated in the prostate cancer with CRPC state, and might provide multiple new 
targets for therapeutic intervention. Moreover, substantial evidences suggest that CRPC 
may not, in fact, be androgen independent, but occurs in a setting of continued AR-
mediated signaling that is driven by the presence of residual tissue androgens. We used 
androgen independent and androgen sensitive cells, LNCaP cells, and examined androgen 
metabolism in the cells.[68] We confirmed that DHT converted from the androgen 
precursors is important in the cellular activity of the cancer cells. This shows that 
metabolism of the androgen in the prostate cancer cells plays an important role even in the 
exacerbation with androgen independent and androgen sensitive state after ADT. This 
conclusion is supported by the evidence that about 30% of recurrent prostate cancers show 
transient clinical responses to secondary or tertiary hormonal manipulation.[69] As a 
consequence, strategies to decrease adrenal cortical androgen production in patients with 
CRPC have been developed and are currently in widespread use. Ryan et al. revealed that 
higher androstenedione levels predict the likelihood of response to ketoconazole, which is 
used as an inhibitor of adrenal androgen synthesis, and improved survival compared with 
patients with lower levels. [70] These data suggest that the therapy with ketoconazole is less 
effective in patients with low levels of androgens at baseline. Ketoconazole therapy as 
secondary hormonal therapies may be less effective in the patients with low androgen levels 
in the prostate. 
7. Clinical-translational advances of castration-resistant prostate cancer 
Recently, encouraging GnRH antagonists and early phase trial results of promising ADT 
agents that interfere with AR signaling for patients with hormone-naive prostate cancer or 
CRPC have been reported. 
7.1 Gonadotrophin-releasing hormone (GnRH) antagonists: Degarelix 
Medical castration using GnRH agonists currently provides the mainstay of ADT for 
prostate cancer. Although effective, these agents only reduce testosterone levels after a delay 
of 14 to 21 days. [71] GnRH antagonists compete with natural GnRH for binding to GnRH 
receptors, thus decreasing or blocking GnRH action in the body. GnRH antagonists induce 
fast and profound LH and follicle-stimulating hormone (FSH) suppressions from the 
pituitary. In men, the reduction in LH subsequently leads to rapid suppression of 
testosterone release from the testes. Unlike the GnRH agonists, which cause an initial 
stimulation of the hypothalamic-pituitary-gonadal axis, leading to a surge in testosterone 
levels, and under certain circumstances, a flare-up of the tumor, GnRH antagonists do not 
cause a surge in testosterone or clinical flare. [72] Clinical flare is a phenomenon that occurs 
in patients with advanced disease, which can precipitate a range of clinical symptoms such 
as bone pain, ureteral obstruction, and spinal cord compression. As testosterone surge does 
not occur with GnRH antagonists, there is no need for patients to receive an antiandrogen as 
flare protection during prostate cancer treatment. GnRH agonists also induce an increase in 
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testosterone levels after each reinjection of the drug a phenomenon that does not occur with 
GnRH antagonists. GnRH antagonists have an immediate onset of action leading to a fast 
and profound suppression of testosterone and are therefore especially valuable in the 
treatment of patients with prostate cancer, where fast control of disease is needed. Abarelix, 
initial GnRH antagonist for prostate cancer, has been linked with immediate-onset systemic 
allergic reactions.[73] Degarelix is a new type of hormonal therapy for prostate cancer 
without stimulation of the release of histamine. [74] The reduction in LH subsequently leads 
to a rapid and sustained suppression of testosterone release from the testes and 
subsequently reduces the size and growth of the prostate cancer. This in turn results in a 
reduction in PSA levels in the patient's blood. Degarelix has an immediate onset of action, 
binding to GnRH receptors in the pituitary gland and blocking their interaction with GnRH. 
[75] The effectiveness of degarelix was recently evaluated in a Phase III, randomised, 12 
month clinical trial (CS21) in 610 patients with prostate cancer, for whom ADT was 
indicated.[76] Patients were randomised to receive treatment with one of two doses of 
degarelix or the GnRH agonist, leuprolide. Both degarelix doses were at least as effective as 
leuprolide at suppressing testosterone to castration levels (<or=0.5 ng/mL) from Day 28 to 
study end (Day 364). Testosterone levels were suppressed significantly faster with degarelix 
than with leuprolide, with nearly all of the degarelix patients achieving castration levels by 
Day 3 of treatment compared with none in the leuprolide group. No patients receiving 
degarelix experienced a testosterone surge compared with 81% of those patients receiving 
leuprolide. Furthermore, degarelix resulted in a significantly faster reduction in PSA levels 
compared with leuprolide indicating faster control of the prostate cancer. Recent results also 
suggest that degarelix therapy may result in longer control of prostate cancer compared 
with leuprolide. [77] As with all hormonal therapies, degarelix is commonly associated with 
hormonal side effects such as hot flushes and weight gain. [76] Due to its mode of 
administration (subcutaneous injection), degarelix is also associated with injection-site 
reactions such as injection-site pain, erythema or swelling. Injection-site reactions are 
usually mild or moderate in intensity and occur predominantly after the first dose, 
decreasing in frequency thereafter. 
7.2 Cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1) inhibitors 
The multifunctional 17-hydroxylase/17,20-lyase encoded by Cytochrome P450, family 17, 
subfamily A, polypeptide 1 (CYP17A1) is a cytochrome P450 enzyme localized to the 
endoplasmic reticulum in the adrenals, testes, placenta and ovaries, and lies at the 
crossroads of sex steroid and glucocorticoid synthesis. It is encoded by a single gene found 
on chromosome 10 in humans. The enzyme possesses both 17-hydroxylase activity and 
C17,20-lyase activity, and requires P450 reductase, cytochrome-b5 reductase (b5), to transfer 
electrons in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) for 
both catalytic activities. The degree of C17,20-lyase activity, modulated by cytochrome-b5, 
determines which metabolic pathway the substrate will follow in terms of sex steroid or 
glucocorticoid formation.[78, 79] Cytochrome-b5 is required for the C17,20 lyase activity, 
and high b5/CYP17A1 ratios are associated with the nearly exclusive production of 
androgens in the testes as opposed to the low ratios observed in the adrenals where 
glucocorticoids are produced.[80, 81] As the critical catalytic step in all androgen 
biosynthesis, therapeutic CYP17A1 inhibition to treat prostate cancer and other androgen 
dependent diseases has been envisioned for over 50 years, with recent discoveries in 
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prostate cancer pathology driving much of the current refocus on CYP17A1 as a therapeutic 
target.[82, 83] Additionally, some evidence suggests that CYP17A1 mRNA and protein 
expression correlate with disease stage and relapse.[84, 85] Despite the strong rational for 
targeting CYP17A1, this target has been largely unexploited with relatively few inhibitors 
progressing to clinical trials and only ketoconazole, an unspecific inhibitor of CYP17A1, in 
widespread clinical use. 
7.3 Abiraterone acetate 
One of CYP17A1 inhibitors, abiraterone acetate, the irreversible inhibitor of 17-
hydroxylase/C17,20-lyase (CYP17A1), is well tolerated and has significant and durable anti-
tumor activity both in patients with chemotherapy-naive prostate cancer and in docetaxel-
treated patients with CRPC. [86] In patients with CRPC, despite ADT, intra-tumoral 
androgen levels remain high, with continued AR signaling. The source of these androgens 
could be adrenal or de novo intra-tumoral synthesis. Researchers tried to inhibit CYP17A1, 
the key enzyme responsible for androgen synthesis, using abiraterone acetate, which is 10-
fold or more potent of inhibition of CYP17A1 than ketoconazole, another inhibitor of 
CYP17A1. The phase II (open-label, single-arm) portion of the trial was an expansion of a 
promising phase I trial reported in 2008. [87] All 42 participants were castrated, and 38 had 
metastases, primarily in bone and/or lymph nodes. Their median age was 70. All received 
oral abiraterone acetate 1,000 mg daily in 28-day cycles. PSA declined at least 50% in 28 of 
the 42 patients (67％); eight patients (19％) had PSA decreases of at least 90%. Of the 24 
patients who had measurable disease on CT scan, 9 (37.5％) had tumor regression that 
constituted a partial response. Further, 16 of these 24 patients (67％) showed no evidence of 
progression at 6 months. Baseline levels of DHEA, DHEA-S, androstenedione and estradiol 
were associated with the increased likelihood of a PSA decline of at least 50%. Adding 
dexamethasone 0.5 mg daily at the time of PSA progression reversed abiraterone acetate 
resistance in 33% of patients. This study and other phase II study revealed that abiraterone 
acetate has significant antitumor activity in post-docetaxel patients with CRPC. [88-90] 
Recent results of the phase III trial of abiraterone acetate in post-docetaxel patients has 
shown an overall survival benefit in advanced CRPC (COU-AA-301). [91] Abiraterone 
acetate is designed to treat these tumors by inhibiting the production of androgen in the 
testes, the adrenal glands and prostate cancer tumors themselves. The Phase III trial 
included 1195 patients from 13 countries whose metastatic, castration-resistant prostate 
cancer had previously been treated with one of two chemotherapeutic agents that included 
docetaxel. Among the 398 patients randomly assigned to receive the corticosteroid 
prednisone plus placebo, median overall survival was 10.9 months. Among the 797 who 
received abiraterone acetate plus prednisone, median survival was 14.8 months. Significant 
differences also emerged between the placebo and treatment groups for all of the trial's 
secondary endpoints, including time to PSA progression, radiographic progression-free 
survival and PSA response rate. The benefits of abiraterone were determined during a pre-
specified interim analysis of the study, prompting the trial's Independent Data Monitoring 
Committee to recommend unblinding the trial, and allowing anyone on the placebo arm to 
be offered abiraterone acetate. Several ongoing trials are examining the agent in earlier 
settings (i.e., a phase III in metastatic CRPC pre-docetaxel, and smaller studies in 
combination with radiation therapy or as neoadjuvant pre-surgery for localized disease). 
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The US Food and Drug Administration (FDA) has approved abiraterone acetate (Zytiga, 
Cougar Biotechnology) in combination with prednisone for the treatment of metastatic 
CRPC in men who have received prior docetaxel chemotherapy. Herein, several potential 
strategies for abiraterone are presented to clarify the clinical utilization of this agent in the 
future. These evidences such as not only decline of PSA levels and the reduction of the 
tumor size but also the evidences such as the symptom improvement and improved 
survival duration are expected in future. 
7.4 Orteronel (TAK-700) [(1S)-1-(6,7-dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-
methylpropan-1-ol] 
Orteronel is a non-steroidal imidazole CYP17A1 inhibitor (IC50 = 28nM) currently in clinical 
trials in prostate cancer patients. The compound was found to be selective for CYP17A1 over 
11-hydroxylase by an impressive 260-fold, and exhibited suppressive effects on 
testosterone biosynthesis in rats and reduction in the weight of prostate and seminal vesicles 
in the rat. [92, 93] Orteronel was also capable of reducing serum testosterone levels down to 
castration level after 8 hours following a single oral administration of 1mg/kg to monkeys. 
A practical asymmetric synthesis of Orteronel has been established in eight steps from 2,3-
dihydroxy naphthalene. This phase I/II, open-label, dose-escalation study assesses the 
safety and tolerability of oral, twice-daily (BID) Orteronel in patients with metastatic CRPC. 
Secondary objectives include assessment of Orteronel efficacy, as shown by PSA response, 
and Orteronel pharmacokinetics. Orteronel >= 300 mg BID appears active and well tolerated 
in patients with metastatic CRPC. The recommended phase II dose is 400 mg BID. [ASCO 
2010 Genitourinary Cancers Symposium] Orteronel is performed on two phase 3 clinical 
trials: one is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel 
plus prednisone compared with placebo plus prednisone in the treatment of men with 
progressive, chemotherapy-naive, metastatic CRPC, the other is in men with metastatic 
CRPC that has progressed following taxane-based therapy. 
7.5 TOK-001 (VN/124-1) [3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene] 
The increased efficacy of TOK-001 in several prostate cancer models both in vitro and in 
vivo is believed to arise from its ability to down regulate the AR as well as competitively 
block androgen binding. [94, 95]. TOK-001 can act by several mechanisms (CYP17A1 
inhibition, competitive inhibition and down-regulation of the AR). In prostate cancer cell 
lines, TOK-001 inhibited the growth of CRPCs, which had increased AR and were no longer 
sensitive to bicalutamide. Indeed, ARMOR1(Androgen Receptor Modulation Optimized for 
Response1) phase1/2 trials with TOK-001 was recently initiated in CRPC patients. 
7.6 3-Hydroxysteroid dehydrogenase inhibitors 
Prostate cancer exhibits robust 3-HSD enzymatic activity, which is required for the AR-
mediated response to -5 adrenal androgens and that 3-HSD may serve as a pharmacologic 
target for the treatment of CRPC. [96] Pharmacologic inhibition of 3-HSD might have 
therapeutic value regardless of the relative contribution of adrenal androgens as opposed to 
de novo steroidogenesis in the reconstitution of intratumoral testosterone and DHT. We 
showed that trilostane , a 3-HSD inhibitor, actually inhibits the in situ conversion of DHEA 
to androstenedione in prostate cancer cells, suggesting a new therapeutic target to more 
efficiently suppress intracellular androgen levels.[97] However, trilostane has a direct 
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androgenic ability in cancer cells with mutated or wild-type AR. Trilostane should be used 
with particular concern when treating prostate cancer, possibly suggesting the combination 
of trilostane and an AR antagonist such as bicalutamide or designing an inhibitor of 3-HSD 
free of AR agonist activity. 
7.7 Apoptone (HE3235) (17-ethynyl-5-androstan-3, 17-diol) 
A novel androstane steroid, Apoptone (HE3235), an orally bioavailable synthetic analogue 
of 3-androstanediol, has a significant inhibitory activity for 5'-androstenediol-stimulated 
LNCaP proliferation. [98, 99] Apoptone exhibits a wide range of effects, including alteration 
of androgen receptor signaling and reductions in levels of intratumoral androgens. This 
inhibitory activity is accompanied by an increase in the number of apoptotic cells. Animal 
studies have confirmed the cytoreductive activity of apoptone on LNCaP tumours. The 
results suggest that this compound may be of clinical use in CRPC. From the results of 
phase I/II clinical trial, apoptone is a novel, orally delivered agent with clinical activity in 
advanced CRPC patients. It is well tolerated and has an AUC linear to dose. Based on the 
safety and activity observed, the trial continues to accrue an expansion cohort at 100 
mg/day of patients with chemotherapy-naive CRPC. [100] 
7.8 Inhibitors targeting androgen receptor  
7.8.1 A new androgen receptor antagonist, MDV3100 (Fig. 2) 
As for the conventional anti-androgen, affinity for AR and agonistic activity for AR are 
matters of concern. Because AR signaling appears to drive this cancer, blocking this 
signaling should stop its growth, the researchers theorized, and they went on to develop a 
drug that would do just that. Another novel ADT drug, AR antagonist MDV3100 (a 
diarylthiohydantoins) is a small-molecule, pure AR antagonist that inhibits AR nuclear 
translocation and DNA binding. [101, 102] MDV3100 is generally well tolerated, and shows 
encouraging anti-tumor activity in patients with CRPC. The drug was selected as a result of 
its activity in models of AR over-expression, in which conventional anti-androgens develop 
agonist properties. Currently available agents in the setting of AR over-expression actually 
act as agonists, rather than antagonists, so they actually make the disease worse, while 
MDV3100 has no known agonist activity. MDV3100 has demonstrated activity in models of 
bicalutamide-resistant prostate cancer. The results come from a phase 1/2 trial 
(NCT00510718) of 140 men, 65 of whom were chemotherapy-naive. Patients with 
progressive, metastatic CRPC were enrolled in dose-escalation cohorts of three to six 
patients and given an oral daily dose of MDV3100 from 30 mg to 600mg. The primary 
objective was to identify the safety and tolerability profile of MDV3100 and to establish the 
maximum tolerated dose. They noted antitumor effects at all doses, including decreases in 
serum prostate-specific antigen of 50% or more in 78 (56%) patients, responses in soft tissue 
in 13 (22%) of 59 patients, stabilized bone disease in 61 (56%) of 109 patients, and conversion 
from unfavorable to favorable circulating tumor cell counts in 25 (49%) of the 51 patients. 
PET imaging of 22 patients to assess androgen-receptor blockade showed decreased (18)F-
fluoro-5-dihydrotestosterone binding at doses from 60 mg to 480 mg per day (range 20-
100%). The median time to progression was 47 weeks (95% CI 34-not reached) for 
radiological progression. The maximum tolerated dose for sustained treatment (>28 days) 
was 240 mg. The most common grade 3-4 adverse event was dose-dependent fatigue (16 
[11%] patients), which generally resolved after dose reduction. The encouraging antitumor  
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Fig. 2. The nuclear translocation and DNA binding on androgen receptors (AR) of 
androgens in the prostate cancer cells and action mechanisms of conventional AR 
antagonists and a new AR antagonist, MDV3100. (a) Conventional AR antagonists block 
AR with antagonistic action competitively in the prostate cancer cells. (b) Conventional 
AR antagonists showed agonistic activity in cells with increased AR levels; this 
antagonist-agonist conversion was associated with alterations in the recruitment of 
coactivators and corepressors to the promoters of AR target genes. Increased levels of AR 
confer resistance to anti-androgens by amplifying signal output from low levels of 
residual ligands, and by altering the normal response to antagonists. (c) MDV3100 is a 
pure AR antagonist that inhibits AR nuclear translocation and DNA binding. The affinity 
with AR of MVD3100 is stronger than that of conventional anti-androgens. MDV3100 has 
no known agonist activity for AR. 
activity with MDV3100 in CRPC validates preclinical studies that have implicated AR 
signaling as a driver of this disease. MDV3100 is performed on two phase 3 clinical trials: 
one is a randomized, double-blind, multicenter, phase 3 study evaluating MDV3100 
compared with placebo in the treatment of men with progressive, chemotherapy-naive, 
metastatic CRPC (PREVAIL), the other is in men with metastatic CRPC that has progressed 
following taxane-based therapy (AFFIRM). 
ARN-509 is also an AR antagonist that inhibits nuclear translocation and DNA binding of 
the receptor, thereby modulating expression of genes that drive prostate cancer growth. 
Phase 1/2 clinical trial of ARN-509 in patients with CRPC was announced. (NCT01171898) 
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7.8.2 An inhibitor of the amino terminal domain (NTD) of the AR: EPI-001 
AR is activated by androgen or by other factors when androgen is removed, resulting in the 
transactivation of the amino terminal domain (NTD) of AR and AR binding to androgen 
response elements (AREs) in the promoters of androgen-regulated genes. All current 
therapies that target the AR are dependent on the presence of its C-terminal ligand-binding 
domain (LBD). A library of extracts from marine sponges for an inhibitor of AR NTD 
transactivation were screened and the small molecule EPI-001 was identified, which 
inhibited transcriptional regulation of androgen-regulated genes, but not those regulated by 
the related progesterone and glucocorticoid steroid receptors. [103] Importantly, EPI-001 
was effective at inhibiting both ligand-dependent and ligand-independent transactivation of 
AR, as well as inhibiting constitutively active AR splice variants that are devoid of LBD. 
EPI-001 has a new mode of action, as it targets the transactivation of AR regardless of the 
presence of androgen, and is a promising therapy to delay the progression of CRPC. 
8. The prospects of the androgen deprivation therapy on the ground of 
androgen milieu in the prostate 
Conventional ADTs that we have used cannot decrease DHT levels in the prostate 
sufficiently to restrain the growth of the cancer in patient with aggressive prostate cancer, as 
we mentioned above. The androgen levels in blood were low; however, it became clear that 
the AR signals play important roles for progress of the cancers from the studies of the 
prostate cancer that became exacerbation after ADT. The androgen milieu in men with high 
Gleason score prostate cancer is probably less affected by conventional ADT than that in 
men with low score cancer, which was suggested to be associated with adrenal androgen 
levels. In patients treated with ADT the pituitary-adrenal axis mediated by 
adrenocorticotropic hormone has a central role in the regulation of androgen synthesis. 
Adrenocorticotropic hormone mediated androgen synthesis is a potential target for 
advanced ADT. Importantly, the suboptimal suppression of androgen activity in the 
prostate cancer may account for the heterogeneity in treatment effect observed across 
individual patients, and, moreover, may contribute to the outgrowth of resistant prostate 
cancer clones adapted to survive in a low androgen environment, suggesting that more 
effective methods for suppressing the androgen axis in the tumoral microenvironment are 
required. From the results of the high reactivity of a CYP17A1 inhibitor and a new AR 
antagonist for patients with CRPC, the androgen syntheses and the maintenances of the AR 
signal system in the prostate cancer play important roles in etiological mechanisms of 
CRPC. As for the ADT for the patients with aggressive prostate cancer, it is important to 
restrain productions of testosterone and DHT and to restrain AR activity together with 
castration from early period of treatment. The results with new ADT agents, such as 
MDV3100 and abiraterone acetate seem to validate the hypothesis that androgens and the 
AR are vital to progression of metastatic CRPC. 
9. Conclusions 
The patients with prostate cancer of high Gleason score have low DHT levels in the prostatic 
tissue. Biologically aggressive prostate cancer can occur under a low DHT level 
environment where the prostate cancer of a low malignancy with high DHT dependency 
cannot easily occur. Conventional ADTs that we have used cannot decrease DHT levels in 
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the prostate sufficiently to restrain the growth of the cancer in patients with aggressive 
prostate cancer. Persistent levels of DHT in the prostate after castration are derived from 
adrenal androgens in the prostate. The androgen milieu in men with high Gleason score 
prostate cancer is probably less affected by conventional ADT than that in men with low 
score cancer, which was suggested to be associated with adrenal androgen levels. In patients 
treated with ADT the pituitary-adrenal axis mediated by adrenocorticotropic hormone has a 
central role in the regulation of androgen synthesis. These locally produced androgens can 
play important roles in the pathogenesis and development of prostate cancer. AR signaling 
pathway is an important mechanism in proliferation of aggressive prostate cancer during 
ADT. AR transcriptional activity is reactivated in CRPC and identifies the intracellular 
conversion of adrenal androgens to DHT as a mechanism mediating this reactivation. New 
ADTs using CYP17A1 inhibitors such as abiraterone acetate and AR antagonists such as 
MDV3100 for patients with CRPC, which will break through the limitation of the efficacy of 
conventional ADTs that have been used for nearly 70 years, have been developing. 
Therefore, it is important to examine the status of in situ androgen metabolism and/or the 
AR signal system in detail in order to improve the clinical response to ADT in patients 
diagnosed with biologically aggressive prostate cancer from now on. 
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